Glutathione Transferase-M2-2 Secreted from Glioblastoma Cell Protects SH-SY5Y Cells from Aminochrome Neurotoxicity

Neurotoxicity Research

Volumn 27, Issue 3, 2015, Pages 217-228

  Cuevas, Carlos ^a   Huenchuguala, Sandro ^a   Muñoz, Patricia ^a   Villa, Monica ^a   Paris, Irmgard ^a,b   Mannervik, Bengt ^c   Segura Aguilar, Juan ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSIDAD SANTO TOMÁS   (Chile)

^c STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

Aminochrome; Dopaminergic neurons; Glia cells; Glutathione transferase; Neuroprotection; Parkinson s disease

Indexed keywords

AMINOCHROME; CARBON 14; DOPAMINE; GLUTATHIONE TRANSFERASE M2; IMIPRAMINE; NOMIFENSINE; QUINONE DERIVATIVE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; AMINOCHROME 1; GLUTATHIONE S-TRANSFERASE MU 2; GLUTATHIONE TRANSFERASE; INDOLE DERIVATIVE; NEUROPROTECTIVE AGENT;

ARTICLE; ASTROCYTE; CELL PROTECTION; CELL TRANSPORT; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENZYME RELEASE; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; NEUROTOXICITY; PRIORITY JOURNAL; PROTEIN FUNCTION; CELL DEATH; DOSE RESPONSE; DRUG EFFECTS; GLIOBLASTOMA; METABOLISM; NEUROBLASTOMA; TUMOR CELL LINE;

CELL DEATH; CELL LINE, TUMOR; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GLIOBLASTOMA; GLUTATHIONE TRANSFERASE; HUMANS; INDOLEQUINONES; NEUROBLASTOMA; NEUROPROTECTIVE AGENTS;

EID: 84925460878     PISSN: 10298428     EISSN: 14763524     Source Type: Journal    
DOI: 10.1007/s12640-014-9500-1     Document Type: Article

References (51)

1. Aguirre P, Urrutia P, Tapia V, Villa M, Paris I, Segura-Aguilar J, Núñez MT (2012) The dopamine metabolite aminochrome inhibits mitochondrial complex I and modifies the expression of iron transporters DMT1 and FPN1. Biometals 25:795–803
2. Arriagada C, Paris I, Sanchez de las Matas MJ, Martinez-Alvarado P, Cardenas S, Castaneda P, Graumann R, Perez-Pastene C, Olea-Azar C, Couve E, Herrero MT, Caviedes P, Segura-Aguilar J (2004) On the neurotoxicity of leukoaminochrome o-semiquinone radical derived of dopamine oxidation: mitochondria damage necrosis and hydroxyl radical formation. Neurobiol Dis 16:468–477
3. Baez S, Segura-Aguilar J, Widersten M, Johansson AS, Mannervik B (1997) Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes. Biochem J 324:25–28
4. Banerjee R, Vitvitsky V, Garg SK (2008) The undertow of sulphur metabolism on glutamatergic neurotransmission. Trends Biochem Sci 33:413–419
5. Bisaglia M, Mammi S, Bubacco L (2007) Kinetic and structural analysis of the early oxidation products of dopamine: analysis of the interactions with alpha-synuclein. J Biol Chem 282:15597–15605
6. Blackinton J, Lakshminarasimhan M, Thomas KJ, Ahmad R, Greggio E, Raza AS, Cookson MR, Wilson MA (2009) Formation of a stabilized cysteine sulfinic acid is critical for the mitochondrial function of the parkinsonism protein DJ-1. J Biol Chem 284:6476–6485
7. Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K (2004) Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res 318:121–134
8. Canet-Avilés RM, Wilson MA, Miller DW, Ahmad R, McLendon C, Bandyopadhyay S, Baptista MJ, Ringe D, Petsko GA, Cookson MR (2004) The Parkinson’s disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci USA 101:9103–9108
9. Carstam R, Brinck C, Hindemith-Augustsson A, Rorsman H, Rosengren E (1991) The neuromelanin of the human substantia nigra. Biochim Biophys Acta 1097:152–160
10. Cheng FC, Kuo JS, Chia LG, Dryhurst G (1996) Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson’s disease. J Neural Transm 103:433–446
11. Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr (2001) Kinetic stabilization of the α-synuclein protofibril by a dopamine-a α-synuclein adduct. Science 294:1346–1349
12. Dagnino-Subiabre A, Cassels BK, Baez S, Johansson AS, Mannervik B, Segura-Aguilar J (2000) Glutathione transferase M2-2 catalyzes conjugation of dopamine and dopa o-quinones. Biochem Biophys Res Commun 274:32–36
13. Dibenedetto D, Rossetti G, Caliandro R, Carloni P (2013) A molecular dynamics simulation-based interpretation of nuclear magnetic resonance multidimensional heteronuclear spectra of α-synuclein·dopamine adducts. Biochemistry 52:6672–6683
14. Dringen R, Hirrlinger J (2003) Glutathione pathways in the brain. Biol Chem 384:505–516
15. Ericson C, Georgievska B, Lundberg C (2005) Ex vivo gene delivery of GDNF using primary astrocytes transduced with a lentiviral vector provides neuroprotection in a rat model of Parkinson’s disease. Eur J Neurosci 22:2755–2764
16. Gardaneh M, Gholami M, Maghsoudi N (2011) Synergy between glutathione peroxidase-1 and astrocyes growth factors protects dopaminergic neurons against 6-hydroxydopamine. Rejuvenation Res 14:195–204
17. Huenchuguala S, Muñoz P, Zavala P, Villa M, Cuevas C, Ahumada U, Graumann R, Nore BF, Couve E, Mannervik B, Paris I, Segura-Aguilar J (2014) Glutathione transferase mu 2 protects glioblastoma cells against aminochrome toxicity by preventing autophagy and lysosome dysfunction. Autophagy 10:618–630
18. Johansson A-S, Bolton-Grob R, Mannervik B (1999) Use of silent mutations in cDNA encoding human glutathione transferase M2-2 for optimized expression in escherichia coli. Protein Expr Purif 17:105–112
19. Koh K, Lee K, Ahn JH, Kim S (2009) Human cytomegalovirus infection downregulates the expression of glial fibrillary acidic protein in human glioblastoma U373MG cells: identification of viral genes and protein domains involved. J Gen Virol 90:954–962
20. Lafon-Cazal M, Adjali O, Galéotti N, Poncet J, Jouin P, Homburger V, Bockaert J, Marin P (2003) Proteomic analysis of astrocytic secretion in the mouse. Comparison with the cerebrospinal fluid proteome, J Biol Chem 278:24438–24448
21. LaVoie MJ, Ostaszewski BL, Weihofen A, Schlossmacher MG, Selkoe DJ (2005) Dopamine covalently modifies and functionally inactivates parkin. Nat Med 11:1159–1161
22. Linert W, Herlinger E, Jameson RF, Kienzl E, Jellinger K, Youdim MB (1996) Dopamine 6-hydroxydopamine iron and dioxygen–their mutual interactions and possible implication in the development of Parkinson’s disease. Biochim Biophys Acta 1316:160–168
23. Lozano J, Muñoz P, Nore BF, Ledoux S, Segura-Aguilar J (2010) Stable expression of short interfering RNA for DT-diaphorase induces neurotoxicity. Chem Res Toxicol 23:1492–1496
24. McKenna MC (2007) The glutamate-glutamine cycle is not stoichiometric: fates of glutamate in brain. J Neurosci Res 85:3347–3358
25. Morris MJ, Craig SJ, Sutherland TM, Board PG, Casarotto MG (2009) Transport of glutathione transferase-fold structured proteins into living cells. Biochim Biophys Acta 1788:676–685
26. Muñoz P, Huenchuguala S, Paris I, Segura-Aguilar J (2012a) Dopamine oxidation and autophagy, Parkinsons Dis. doi:10.1155/2012/920953
27. Muñoz P, Paris I, Sanders LH, Greenamyre JT, Segura-Aguilar J (2012b) Overexpression of VMAT-2 and DT-diaphorase protects substantia nigra-derived cells against aminochrome neurotoxicity. Biochim Biophys Acta 1822:1125–1136
28. Nehlig A, Coles JA (2007) Cellular pathways of energy metabolism in the brain: is glucose used by neurons or astrocytes? Glia 55:1238–1250
29. Norris EH, Giasson BI, Hodara R, Xu S, Trojanowski JQ, Ischiropoulos H, Lee VM (2005) Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J Biol Chem 280:21212–22129
30. Paris I, Perez-Pastene C, Cardenas S, Iturriaga-Vasquez P, Muñoz P, Couve E, Caviedes P, Segura-Aguilar J (2010) Aminochrome induces disruption of actin alpha- and beta-tubulin cytoskeleton networks in substantia-nigra-derived cell line. Neurotox Res 18:82–92
31. Paris I, Muñoz P, Huenchuguala S, Couve E, Sanders LH, Greenamyre JT, Caviedes P, Segura-Aguilar J (2011) Autophagy protects against aminochrome-induced cell death in substantia nigra-derived cell line. Toxicol Sci 121:376–388
32. Pellerin L (2008) Brain energetics (thought needs food). Curr Opin Clin Nutr Metab Care 11:701–705
33. Pellerin L, Bouzier-Sore AK, Aubert A, Serres S, Merle M, Costalat R, Magistretti PJ (2007) Activity-dependent regulation of energy metabolism by astrocytes: an update. Glia 55:1251–1262
34. Rosengren E, Linder-Eliasson E, Carlsson A (1985) Detection of 5-S-cysteinyldopamine in human brain. J Neural Transm 63:247–253
35. Safi R, Gardaneh M, Panahi Y, Maghsoudi N, Zaefizadeh M, Gharib E (2012) Optimized quantities of GDNF overexpressed by engineered astrocytes are critical for protection of neuroblastoma cells against 6-OHDA toxicity. J Mol Neurosci 46:654–665
36. Schousboe A, Bak LK, Sickmann HM, Sonnewald U, Waagepetersen HS (2007) Energy substrates to support glutamatergic and GABAergic synaptic function: role of glycogen glucose and lactate. Neurotox Res 12:263–268
37. Segura-Aguilar J, Lind C (1989) On the mechanism of the Mn3(+)-induced neurotoxicity of dopamine:prevention of quinone-derived oxygen toxicity by DT diaphorase and superoxide dismutase. Chem Biol Interact 72:309–324
38. Segura-Aguilar J, Baez S, Widersten M, Welch CJ, Mannervik B (1997) Human class Mu glutathione transferases in particular isoenzyme M2-2 catalyze detoxication of the dopamine metabolite aminochrome. J Biol Chem 272:5727–5731
39. Segura-Aguilar J, Metodiewa D, Welch CJ (1998) Metabolic activation of dopamine o-quinones to o-semiquinones by NADPH cytochrome P450 reductase may play an important role in oxidative stress and apoptotic effects. Biochim Biophys Acta 1381:1–6
40. Segura-Aguilar J, Paris I, Muñoz P, Ferrari E, Zecca L, Zucca FA (2014) Protective and toxic roles of dopamine in Parkinson’s disease. J Neurochem 129:898–915
41. Shen XM, Xia B, Wrona MZ, Dryhurst G (1996) Synthesis redox properties in vivo formation and neurobehavioral effects of N-acetylcysteinyl conjugates of dopamine possible metabolites of relevance to Parkinson’s disease. Chem Res Toxicol 9:1117–1126
42. Skindersoe ME, Rohde M, Kjaerulff S (2012) A novel and rapid apoptosis assay based on thiol redox status. Cytometry 81A:430–436
43. Strolin-Benedetti M, Dostert P, Tipton KF (1992) Developmental aspects of the monoamine-degrading enzyme monoamine oxidase. Dev Pharmacol Ther 18:191–200
44. Takeda H, Inazu M, Matsumiya T (2002) Astroglial dopamine transport is mediated by norepinephrine transporter. Naunyn Schmiedebergs Arch Pharmacol 366:620–623
45. Trempe JF, Fon EA (2013) Structure and function of Parkin PINK1 and DJ-1 the three musketeers of neuroprotection. Front Neurol 19:438
46. Tse DC, McCreery RL, Adams RN (1976) Potential oxidative pathways of brain catecholamines. J Med Chem 19:37–40
47. Van Laar VS, Mishizen AJ, Cascio M, Hastings TG (2009) Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells. Neurobiol Dis 34:487–500
48. Westlund KN, Denne RM, Rose RM, Abell CW (1988) Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem. Neuroscience 25:439–456
49. Yang CZ, Zhao R, Dong Y, Chen XQ, Yu AC (2008) Astrocyte and neuron intone through glutamate. Neurochem Res 33:2480–2486
50. Zafar KS, Siegel D, Ross D (2006) A potential role for cyclized quinones derived from dopamine DOPA and 34-dihydroxyphenylacetic acid in proteasomal inhibition. Mol Pharmacol 70:1079–1086
51. Zhou ZD, Lim TM (2009) Dopamine (DA) induced irreversible proteasome inhibition via DA derived quinones. Free Radic Res 43:417–430